Dec. 20, 2013 (Life Technologies Press Release) -- Life Technologies Corporation (NASDAQ: LIFE) announced that Cynvenio Biosystems, a molecular testing company focused on liquid biopsy assay development, has joined the Ion Certified Service Provider (CSP) program. Cynvenio’s LiquidBiopsy® technology is a proprietary platform for recovering circulating tumor cells at purity levels high enough to enable detection by next-generation sequencing.
November 25, 2013 - Cynvenio announced that the company’s automated LiquidBiopsy platform has been independently evaluated and selected by Frost & Sullivan as the winner of their 2013 Technology Innovation Leadership Award.
October 3, 2013 – Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in blood, today launched a new weapon in the fight against breast cancer, the ClearID Breast Cancer monitoring program.
July 9, 2013 – Cynvenio today announced certification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 for its genomic sequencing laboratory in Westlake Village, California.
May 24, 2013 – Cynvenio announced that clinical data from two research collaborations in breast and prostate cancer will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 taking place May 31-June 4, 2013 in Chicago. These data highlight the company’s progress in the molecular analysis of circulating tumor cells (CTC) by next generation sequencing.
April 18, 2013 – Cynvenio announced that Dr. Paul Dempsey, its Chief Scientific Officer, has been named the top Healthcare Research Executive of 2013 by the Los Angeles Business Journal.